Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

The association between the PTPN22 1858C>T variant and type 1 diabetes depends on HLA risk and GAD65 autoantibodies.

Maziarz M, Janer M, Roach JC, Hagopian W, Palmer JP, Deutsch K, Sanjeevi CB, Kockum I, Breslow N, Lernmark A; Swedish Childhood Diabetes Register; Diabetes Incidence in Sweden Study Group.

Genes Immun. 2010 Jul;11(5):406-15. doi: 10.1038/gene.2010.12. Epub 2010 May 6.

2.

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.

Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C.

Nat Med. 2010 Apr;16(4):406-12. doi: 10.1038/nm.2110. Epub 2010 Mar 28.

3.

Interferon-alpha: a therapeutic target in systemic lupus erythematosus.

Crow MK.

Rheum Dis Clin North Am. 2010 Feb;36(1):173-86, x. doi: 10.1016/j.rdc.2009.12.008.

4.

Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C.

Yamazaki M, Sato A, Takeda T, Komatsu M.

Intern Med. 2010;49(5):403-7. Epub 2010 Mar 1.

5.

Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alpha-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis.

Mensah KA, Mathian A, Ma L, Xing L, Ritchlin CT, Schwarz EM.

Arthritis Rheum. 2010 Apr;62(4):1127-37. doi: 10.1002/art.27312.

6.

Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis.

van Baarsen LG, Bos WH, Rustenburg F, van der Pouw Kraan TC, Wolbink GJ, Dijkmans BA, van Schaardenburg D, Verweij CL.

Arthritis Rheum. 2010 Mar;62(3):694-704. doi: 10.1002/art.27294.

8.

Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment.

van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, Dijkmans BA, Tak PP, Verweij CL.

Arthritis Res Ther. 2010;12(1):R11. doi: 10.1186/ar2912. Epub 2010 Jan 22.

9.

Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7.

Daffis S, Suthar MS, Szretter KJ, Gale M Jr, Diamond MS.

PLoS Pathog. 2009 Oct;5(10):e1000607. doi: 10.1371/journal.ppat.1000607. Epub 2009 Oct 2.

10.

Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.

Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H.

Diabetes Res Clin Pract. 2009 Nov;86(2):e19-21. doi: 10.1016/j.diabres.2009.08.009. Epub 2009 Sep 9.

PMID:
19744739
11.

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis.

Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R.

Brain. 2009 Dec;132(Pt 12):3353-65. doi: 10.1093/brain/awp228.

PMID:
19741051
12.

Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes.

Rother KI, Brown RJ, Morales MM, Wright E, Duan Z, Campbell C, Hardin DS, Popovic J, McEvoy RC, Harlan DM, Orlander PR, Brod SA.

Diabetes Care. 2009 Jul;32(7):1250-5. doi: 10.2337/dc08-2029. Erratum in: Diabetes Care. 2009 Sep;32(9):1751.

13.

Peripheral blood gene expression profiling in Sjögren's syndrome.

Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, Segal B, Rhodus NL, Moser KL.

Genes Immun. 2009 Jun;10(4):285-96. doi: 10.1038/gene.2009.20. Epub 2009 Apr 30.

14.

Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis.

Mirandola SR, Hallal DE, Farias AS, Oliveira EC, Brandão CO, Ruocco HH, Damasceno BP, Santos LM.

Int Immunopharmacol. 2009 Jul;9(7-8):824-30. doi: 10.1016/j.intimp.2009.03.004. Epub 2009 Mar 14.

PMID:
19289181
15.

Interferon-induced Mx proteins in brain tissue of multiple sclerosis patients.

Al-Masri AN, Heidenreich F, Walter GF.

Eur J Neurol. 2009 Jun;16(6):721-6. doi: 10.1111/j.1468-1331.2009.02573.x. Epub 2009 Feb 19.

PMID:
19236454
16.

IFN-alpha can both protect against and promote the development of type 1 diabetes.

Wong FS, Wen L.

Ann N Y Acad Sci. 2008 Dec;1150:187-9. doi: 10.1196/annals.1447.031.

PMID:
19120292
17.

Mutation of the IFNAR-1 receptor binding site of human IFN-alpha2 generates type I IFN competitive antagonists.

Pan M, Kalie E, Scaglione BJ, Raveche ES, Schreiber G, Langer JA.

Biochemistry. 2008 Nov 18;47(46):12018-27. doi: 10.1021/bi801588g. Epub 2008 Oct 21.

PMID:
18937499
19.

Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice.

Li Q, Xu B, Michie SA, Rubins KH, Schreriber RD, McDevitt HO.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12439-44. doi: 10.1073/pnas.0806439105. Epub 2008 Aug 20.

20.

Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.

Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK.

Arthritis Rheum. 2008 Aug;58(8):2481-7. doi: 10.1002/art.23613.

Supplemental Content

Support Center